United Kingdom · Question · Written question
UIN 106958
Sodium Valproate: Health Education
Original
Introduced
20 January 2026
Last action
27 January 2026 · Answer
Status
Answered
Sponsors
—
Subjects
Education
Source updated
27 January 2026
Summary
To ask the Secretary of State for Health and Social Care, what assessment has been made of the MHRA’s effectiveness at communicating known risks of sodium valproate, particularly in pregnancy, prior to 2018.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
20 January 2026
Written question
To ask the Secretary of State for Health and Social Care, what assessment has been made of the MHRA’s effectiveness at communicating known risks of sodium valproate, particularly in pregnancy, prior to 2018.
Source: Commons
27 January 2026
Answer
As with all medicines, the safety of valproate has been kept under continual review by the Medicines and Healthcare products Regulatory Agency (MHRA), ensuring the product information reflects what is known about valproate.The known risks of valproate are...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2026-01-20/106958
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1873485
- uk · wq-1873485 · source updated 27 January 2026